Document text
Principal Investigator: JEFFREY SCHLOM
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2021
Award: $1,593,930
Funding agency: National Cancer Institute
INTERROGATION OF THE CELLULAR IMMUNOME OF CANCER PATIENTS WITH REGARD TO THE COVID-19 PANDEMIC. While vaccines directed against the SARS-CoV-2 spike protein will have varying degrees of effectiveness in preventing SARS-CoV-2 infections, the severity of infection will be determined by multiple host factors including the ability of immune cells to lyse virus- infected cells. This review will discuss the complexity of both adaptive and innate immunomes and how a flow-based assay can detect up to 158 distinct cell subsets in the periphery. This assay has been employed to show the effect of age on differences in specific immune cell subsets, and the differences in the immunome between healthy donors and age-matched cancer patients. Also reviewed are the numerous soluble factors, in addition to cytokines, that may vary in the pathogenesis of SARS-CoV-2 infections and may also be employed to help define the effectiveness of a given vaccine or other antiviral agents. Various steroids have been employed in the management of autoimmune adverse events in cancer patients receiving immunotherapeutics and may be employed in the management of SARS-CoV-2 infections. The influence of steroids on multiple immune cells subsets will also be discussed. [] PHASE I STUDY OF A MULTITARGETED RECOMBINANT AD5 PSA/MUC-1/BRACHYURY-BASED IMMUNOTHERAPY VACCINE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC). Antitumor vaccines targeting tumor- associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1-, E2b-] targeting three TAAs, prostate-specific antigen (PSA), brachyury and MUC-1, has been developed. Both brachyury and the C-terminus of MUC-1 are overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and have been shown to play an important role in resistance to chemotherapy, epithelial-mesenchymal transition, and metastasis. The transgenes for PSA, brachyury, and MUC-1 all contain epitope modifications for the expression of CD8+ T-cell enhancer agonist epitopes. We report here the first-in-human trial of this vaccine platform. Patients with mCRPC were given concurrently three vaccines targeting PSA, brachyury, and MUC-1 at 5x10 to the 11th viral particles (VP) each, subcutaneously every 3 weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every 8 weeks for 1 year (dose-expansion cohort only). The primary objective was to determine the safety and the recommended phase II dose. Immune assays and clinical responses were evaluated. Eighteen patients with mCRPC were enrolled between July 2018 and September 2019 and received at least one vaccination. Median PSA was 25.58 ng/mL (range, 0.65-1006 ng/mL). The vaccine was tolerable and safe, and no grade 3 treatment-related adverse events or dose-limiting toxicities (DLTs) were observed. One patient had a partial response, while five patients had confirmed PSA decline and five had stable disease for 6 months. Median progression-free survival was 22 weeks (95% CI: 19.1 to 34). Seventeen (100%) of 17 patients mounted T-cell responses to at least one TAA, whereas 8 (47%) of 17 patients mounted immune responses to all three TAAs. Multifunctional T-cell responses to PSA, MUC-1, and brachyury were also detected after vaccination in the majority of the patients. Ad5 PSA/MUC-1/brachyury vaccine is well tolerated. The primary end points were met and there were no DLTs. The recommended phase II dose is 5x10 to the 11th VP. The vaccine demonstrated clinical activity, including one partial response and confirmed PSA responses in five patients. Three patients with prolonged PSA responses received palliative radiation therapy. Further research is needed to evaluate the clinical benefit and immunogenicity of this vaccine in combination with other immuno-oncology agents and/or palliative radiation therapy. [] IMMUNOLOGY OF LYNCH SYNDROME. Patients with Lynch syndrome have a high probability of developing colorectal and other carcinomas. This review provides a comprehensive assessment of the immunologic aspects of Lynch syndrome pathogenesis and provides an overview of potential immune interventions for patients with Lynch syndrome polyps and Lynch syndrome-associated carcinomas. Immunogenic properties of the majority of Lynch syndrome polyps and associated cancers include microsatellite instability leading to a high mutational burden and the development of novel frameshift peptides, i.e., neoantigens. In addition, patients with Lynch syndrome develop T cell responses in the periphery and in the tumor microenvironment (TME) to tumor-associated antigens, and a proinflammatory cytokine TME has also been identified. However, Lynch syndrome lesions also possess immunosuppressive entities such as alterations in MHC class I antigen presentation, TGF-beta receptor mutations, regulatory T cells, and upregulation of PD-L1 on tumor-associated lymphocytes. The rich immune microenvironment of Lynch syndrome polyps and associated carcinomas provides an opportunity to employ the spectrum of immune-mediating agents now available to induce and enhance host immune responses and/or to also reduce immunosuppressive entities. These agents can be employed in the so-called prevention trials for the treatment of patients with Lynch syndrome polyps and for trials in patients with Lynch syndrome-associated cancers. [] IDENTIFICATION AND VALIDATION OF EXPRESSED HLA-BINDING BREAST CANCER NEOEPITOPES FOR POTENTIAL USE IN INDIVIDUALIZED CANCER THERAPY. Therapeutic regimens designed to augment the immunological response of a patient with breast cancer (BC) to tumor tissue are critically informed by tumor mutational burden and the antigenicity of expressed neoepitopes. Herein we describe a neoepitope and cognate neoepitope-reactive T-cell identification and validation program that supports the development of next-generation immunotherapies. Using GPS Cancer, NantOmics research, and The Cancer Genome Atlas databases, we developed a novel bioinformatic- based approach which assesses mutational load, neoepitope expression, human leukocyte antigen (HLA)-binding prediction, and in vitro confirmation of T-cell recognition to preferentially identify targetable neoepitopes. This program was validated by application to a BC cell line and confirmed using tumor biopsies from two patients with BC enrolled in the Tumor-Infiltrating Lymphocytes and Genomics (TILGen) study. The antigenicity and HLA- A2 restriction of the BC cell line predicted neoepitopes were determined by reactivity of T cells from HLA-A2-expressing healthy donors. For the TILGen subjects, tumor-infiltrating lymphocytes (TILs) recognized the predicted neoepitopes both as peptides and on retroviral expression in HLA-matched Epstein-Barr virus-lymphoblastoid cell line and BC cell line MCF-7 cells; PCR clonotyping revealed the presence of T cells in the periphery with T-cell receptors for the predicted neoepitopes. These high-avidity immune responses were polyclonal, mutation- specific and restricted to either HLA class I or II. Interestingly, we observed the persistence and expansion of polyclonal T-cell responses following neoadjuvant chemotherapy. We demonstrated that our neoepitope prediction program allows for the successful identification of neoepitopes targeted by TILs in patients with BC, providing a means to identify tumor-specific immunogenic targets for individualized treatment, including vaccines or adoptively transferred cellular therapies.
Terms: <2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Adenoviridae><Adenoviruses><Adoptive Transfer><Adverse Experience><Adverse event><Age><Agonist><Antigen Presentation><Antigenic Determinants><Antineoplastic Vaccine><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Autoimmune><Avidity><B7-H1><B7H1><Binding Determinants><Bio-Informatics><Bioassay><Bioinformatics><Biologic Assays><Biological Assay><Biopsy><Brachyury><Brachyury protein><Breast Cancer><Breast Cancer cell line><Breast tumor cell line><Burkitt Herpesvirus><Burkitt Lymphoma Virus><CA-15-3 Antigen><CD274><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><Cancer Patient><Cancer Vaccines><Cancers><Carcinoma><Cell Body><Cell Therapy><Cells><Class I Antigens><Class I Major Histocompatibility Antigens><Clinical><Clinical Treatment><Colon or Rectum><Colorectal><Combined Modality Therapy><Complex Class 1><DF3 Antigen><Data Bases><Databases><Development><Dose><Dose-Limiting><E-B Virus><EB virus><EBV><EC 3.4.21.34><Effectiveness><Enhancers><Enrollment><Episialin><Epithelial><Epithelial Membrane Antigen><Epithelial cancer><Epitopes><Epstein Barr Virus><Familial Nonpolyposis Colon Cancer><Genetic Alteration><Genetic Change><Genetic defect><Genomics><Glycosylated MUC-1><Goals><HHV-4><HHV4><HL-A Antigens><HLA Antigens><HNPCC><Hereditary Colo-rectal Endometrial Cancer Syndrome><Hereditary Colorectal Endometrial Cancer Syndrome><Hereditary Defective Mismatch Repair Syndrome><Hereditary Non-Polyposis Colon Cancer><Hereditary Nonpolyposis Colo-rectal Cancer><Hereditary Nonpolyposis Colo-rectal Neoplasms><Hereditary Nonpolyposis Colon Cancer><Hereditary Nonpolyposis Colorectal Cancer><Hereditary Nonpolyposis Colorectal Neoplasms><Histocompatibility Antigens Class I><Host Factor><Host Factor Protein><Human><Human Herpesvirus 4><Human Leukocyte Antigens><Immune><Immune mediated therapy><Immune response><Immune system><Immunes><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologically Directed Therapy><Immunologics><Immunology procedure><Immunooncology><Immunotherapeutic agent><Immunotherapy><In Vitro><Induction Therapy><Infection><Infectious Mononucleosis Virus><Integration Host Factors><Kallikrein 3><LS/HNPCC><Lesion><Leukocyte Antigens><Lymphatic cell><Lymphocyte><Lymphocytic><Lynch Syndrome><MCF-7><MCF-7 Cell><MCF-7DR><MCF-7WT><MCF7><MCF7 cell><MHC Class I Molecule><MHC Class I Protein><MHC Receptor><MHC class I antigen><MUC-1><MUC-1 Antigen><MUC1><MUC1 antigen><MUC1 gene product><Major Histocompatibility Complex Class 1><Major Histocompatibility Complex Receptor><Malignant Epithelial Neoplasms><Malignant Epithelial Tumors><Malignant Neoplasms><Malignant Tumor><Mediating><Mesenchymal><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Microsatellite Instability><Modern Man><Modification><Muc1 Mucin><Mucin 1><Mucin 1 protein><Mucin Peptide MUC-1><Mucin/Peptide><Multimodal Therapy><Multimodal Treatment><Mutation><NEOADJ><Neoadjuvant><Neoadjuvant Therapy><Neoadjuvant Treatment><Neoplasm Metastasis><Neoplasm Vaccines><P-30 Antigen><PD-L1><PDL-1><PDL1><Pathogenesis><Patients><Peptides><Phase><Phase I Study><Plasma Kallikrein Precursor><Plasma Prekallikrein><Play><Polymorphic Epithelial Mucin><Polyps><Prevention trial><Probability><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Progression-Free Survivals><Property><Prostate Specific Antigen Preproprotein><Prostate-Specific Antigen><Radiation therapy><Radiotherapeutics><Radiotherapy><Receptors, Antigen, T-Cell><Recombinants><Regimen><Regulatory T-Lymphocyte><Reporting><Research><Resistance><Role><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 pathogenesis><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Safety><Secondary Neoplasm><Secondary Tumor><Semenogelase><Seminin><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severities><Stable Disease><Steroid Compound><Steroids><T Brachyury protein><T cell response><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TCGA><TGF-beta Receptors><TGF-β Receptors><The Cancer Genome Atlas><Therapeutic><Toxic effect><Toxicities><Transforming Growth Factor beta Receptors><Transforming Growth Factor β Receptors><Transgenes><Treg><Tumor Antigens><Tumor Tissue><Tumor Vaccines><Tumor-Associated Antigen><Tumor-Infiltrating Lymphocytes><Up-Regulation><Upregulation><Vaccination><Vaccines><Validation><Viral><Virus><age effect><ages><aging effect><allergic/immunologic body system><allergic/immunologic organ system><anti-cancer immunotherapy><anti-tumor immune response><anti-tumor vaccine><anti-viral agents><anti-viral drugs><anti-virals><anticancer immunotherapy><antigen binding><antigen bound><antitumor immune response><antitumor vaccine><base><booster vaccine><cancer antigens><cancer immunotherapy><cancer metastasis><cancer microenvironment><castrate resistant PCa><castrate resistant prostate cancer><castration resistant PCa><castration resistant prostate cancer><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapy><chemotherapy><cohort><colo-rectal><colorectum><combination therapy><combined modality treatment><combined treatment><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><customized therapy><customized treatment><cytokine><data base><design><designing><developmental><enroll><epithelial carcinoma><first in man><first-in-human><gamma-Seminoprotein><genome mutation><hK3 Kallikrein><hereditary non-polyposis colo-rectal cancer><hereditary non-polyposis colorectal cancer><host response><immune drugs><immune microenvironment><immune modulatory intervention><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-oncology><immuno oncology><immuno therapy><immunogenic><immunogenicity><immunointervention><immunologic assay><immunologic assay/test><immunologic preparation><immunologic therapeutics><immunological intervention><immunology oncology><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><individualized cancer therapy><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><lymph cell><lymphoblastoid cell line><malignancy><malignant breast neoplasm><malignant breast tumor><multi-modal therapy><multi-modal treatment><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm/cancer><new vaccines><next generation><next generation vaccines><novel><novel vaccines><oncoimmunology><overexpress><overexpression><palliative><partial response><particle><patient specific therapies><patient specific treatment><peptide I><peripheral blood><personalized cancer therapy><personalized cancer treatment><phase 1 study><prevent><preventing><primary end point><primary endpoint><programmed cell death ligand 1><programmed cell death protein ligand 1><programs><radiation treatment><radio-therapy><regulatory T-cells><resistant><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 pathogenesis><social role><subcutaneous><subdermal><tailored medical treatment><tailored therapy><tailored treatment><thymus derived lymphocyte><treatment with radiation><trial regimen><trial treatment><tumor><tumor cell metastasis><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><tumor-specific antigen><unique treatment><vaccination study><vaccination trial><vaccine for cancer><vaccine for immunotherapy><vaccine immunotherapy><vaccine study><vaccine trial><vaccine-based immunotherapy><vector>